AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
10/07/26	€0.7330	-2.27%	144,000
09/07/26	€0.7500	+1.35%	245,638
08/07/26	€0.7400	-1.99%	270,840
07/07/26	€0.7550	-0.66%	171,340
06/07/26	€0.7600	-1.68%	216,989

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 16:55:00 10/07/2026 BST			5-day change	1st Jan Change
0.7330 ^EUR	-2.27%		-5.17%	-52.28%

07-01	AB Science, successful private placement
06-30	AB Science S.A. announced that it has received ?2.294 million in funding	CI

Market Cap	58.65M 67.05M 54.1M 49.96M 94.81M 6.4B 96.4M 646M 254M 3.15B 252M 246M 10.83B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	58.65M 67.05M 54.1M 49.96M 94.81M 6.4B 96.4M 646M 254M 3.15B 252M 246M 10.83B	EV / Sales 2026 *	48.9x	EV / Sales 2027 *	45.1x
Free-Float	72.29%	Yield 2026 *	-	Yield 2027 *	-

07-01	AB Science, successful private placement
06-30	AB Science S.A. announced that it has received ?2.294 million in funding	CI
06-29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
06-29	AB Science completes Step 3 of a Phase 1 study
06-18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
06-18	AB Science Secures New U.S. Patent for Masitinib
06-17	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
06-10	AB Science presents new data on Masitinib
05-17	AB Science S.A. announced that it has received $2.989368 million in funding	CI
05-13	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-03	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
04-29	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
04-29	AB Science announces successful capital increase

07-10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
07-08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
07-01	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
06-29	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ

AB Science Share Price

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

07-10	AB Science rationalise son portefeuille et se recentre sur deux molécules
07-10	AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
07-08	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG
07-07	Ab Science : Nomination de Stéphane LEDERMANN en qualité de Président Directeur Général
07-01	AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2026

1 day	-2.27%
1 week	-5.17%
Current month	-17.18%
1 month	-19.45%
3 months	-38.40%
6 months	-50.47%
Current year	-52.28%

1 week	0.72	0.78
1 month	0.72	0.94
Current year	0.72	1.61
1 year	0.72	1.73
3 years	0.72	4.46
5 years	0.72	16.68
10 years	0.72	21.75

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	06/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	19/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	31/03/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	10/07/2001
Patrick Moussy BRD	Director/Board Member	-	19/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	26/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
05-19	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
08/02/21	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
01/02/21	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-2.27%	-5.17%	-47.34%	-81.03%	67.05M
MERCK & CO., INC.	-1.22%	-4.65%	+47.04%	+12.35%	305B
MERCK KGAA	+0.07%	-4.09%	+22.06%	-4.22%	69.44B
HALOZYME THERAPEUTICS, INC.	-3.08%	-4.09%	+32.22%	+104.18%	9.04B
KYOWA KIRIN CO., LTD.	-1.23%	-0.84%	+6.26%	+1.52%	8.56B
SK BIOPHARMACEUTICALS CO., LTD.	+2.74%	-4.41%	-16.77%	+12.26%	4.3B
BETTA PHARMACEUTICALS CO., LTD.	+1.60%	-9.66%	+14.44%	+27.14%	4.09B
YUHAN CORPORATION	+1.63%	-2.70%	-38.89%	+27.08%	3.4B
SUPERNUS PHARMACEUTICALS, INC.	-0.59%	+0.85%	+46.23%	+62.45%	2.81B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+2.24%	-2.33%	+11.41%	-21.98%	2.14B
Average	-0.01%	-2.53%	+7.66%	+13.98%	40.9B
Weighted average by Cap.	-0.93%	-3.41%	+39.70%	+11.76%

	2026 *	2027 *
Net sales	1.2M 1.37M 1.11M 1.02M 1.94M 131M 1.97M 13.22M 5.19M 64.46M 5.15M 5.04M 222M	1.3M 1.49M 1.2M 1.11M 2.1M 142M 2.14M 14.33M 5.63M 69.83M 5.58M 5.46M 240M
Net income	-	-
Net Debt	-	-